Drug safety monitoring in patients of movement disorders of a tertiary care hospital

Indian Journal of Pharmacology

Volumn 42, Issue 4, 2010, Pages 249-251

  Mandal, Ananya ^a   Chatterjee, Suparna ^b   Das, Shyamal Kumar ^c   Mishra, Amar ^c  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c BANGUR INSTITUTE OF NEUROLOGY   (India)

Author keywords

Adverse drug reactions; drug induced movement disorders; movement disorders; pharmacovigilance

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DONEPEZIL; ENTACAPONE; ESCITALOPRAM; HALOPERIDOL; LEVODOPA; METOCLOPRAMIDE; OLANZAPINE; PENICILLAMINE; PHENYTOIN; PRAMIPEXOLE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; SERTRALINE; TETRABENAZINE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROIC ACID; ZOLPIDEM;

ADULT; ARTICLE; CARDIOVASCULAR SYMPTOM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PREVALENCE; SKIN DISEASE; TERTIARY HEALTH CARE; UROGENITAL TRACT DISEASE;

EID: 77956232707     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.68437     Document Type: Article

References (12)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022
2. Gourie Devi M, Gururaj G, Satish Chandra P, Subbakrishna DK. Prevalence of neurological disorders in Bangalore, India: A community based study with a comparison between urban and rural areas. Neuroepidemiology 2004;23:261-268
3. Chouinard G. New nomenclature for drug-induced movement disorders including Tardive dyskinesias. J Clin Psychiatry 2004;65:9-15.
4. Leoni O, Martnoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, et al. Drug prescribing patterns in Parkinson's disease: A pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 2002;11:149-157
5. Askmark H, Antonov K, Aquilonius SM. The increased utilization of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption: A nationwide perspective in Sweden. Parkinsonism Relat Disord 2003;9:271-276
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
7. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with or without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:1323-1328
8. Singh S, Behari M. Verbal and visual memory in patients with early Parkinson's disease: Effect of levodopa. Neurol India 2006;54:33-37
9. Schelosky L, Benke T, Poewe WH. Effects of treatment with trihexyphenidyl on cognitive functions in early Parkinson's disease. J Neural Transm Suppl 1991;33:125-133
10. Naranjo CA, Fornazzari L, Sellers EM. Clinical detection and assessment of drug induced neurotoxicity. Prog Neuropsychopharmacol 1981;5:427-434
11. Drug Analysis Prints: Data on suspected adverse drug reactions [Medicines and Healthcare Products Regulatory Agency Website]. [last updated on 2006]. Available from: http://www.mhra.gov.uk/[last accessed on 2010 Feb 3].
12. Ramesh S, Sagar R. Antipsychotic induced movement disorders. Indian J Med Sci 2001;55:483-487